1. bookVolume 75 (2021): Issue 3 (June 2021)
Journal Details
First Published
14 Sep 2008
Publication timeframe
6 times per year
access type Open Access

“New Kids on the Block” — The Game Changers. The Role of Immune Check Point Blockade in Personalised Treatment of Prostate, Urinary Bladder and Kidney Cancer

Published Online: 22 Jul 2021
Page range: 149 - 157
Received: 12 Jan 2021
Accepted: 02 Mar 2021
Journal Details
First Published
14 Sep 2008
Publication timeframe
6 times per year

Early detection and diagnosis of cancer followed by a personalised approach to treatment is a key and can save lives. It has been an important issue in both the medical and social fields. The search for instruments and/or diagnostics tools able to detect cancers at an early stage has led to consideration of the usage of various approaches, such as exhaled air, biomarkers in blood, urine testing as well as imaging techniques. This actual time and everything that is happening around us could be characterised as a strange and very unpredictable time. This comparison could be made not only due to the actual coronavirus situation, but also the same can be noticed in the personalised medicine of the second decade of 21st century — by means of check point inhibitors. The old dogmas, for instance, chemotherapy and metastasis-surgery are being appended with new diagnostic and therapy use of checkpoint inhibitors. What exactly is the checkpoint blockade and how it is working in three tumour modalities: bladder cancer, prostate cancer and renal cancer. Our study group will provide a brief and detailed, guideline-compliant outline. The aim of this review was to provide a summary of the current state of the art of immune therapy as potential treatment of prostate, urinary bladder, and kidney cancer.


Balar, A. V. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet, 389, 67–76. Search in Google Scholar

Balar, A. V. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol., 18, 1483–1492. Search in Google Scholar

Beer, T. M. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl. J. Med., 371, 424–433 Search in Google Scholar

Bellmunt, J. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Engl. J. Med., 376, 1015–1026. Search in Google Scholar

Bellmunt, J. (2009). Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol., 27, 4454–4461. Search in Google Scholar

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., Freeman, G. J. (2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 27 (1), 111–122. Search in Google Scholar

Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L., Woo, H. H. (2017). Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis., 20, 352–360. Search in Google Scholar

Cameron, F., Whiteside, G., Perry, C. (2011). Ipilimumab: First global approval. Drugs, 71 (8), 1093–1104. Search in Google Scholar

Chi, K. N. (2019). Apalutamide for metastatic, castration-sensitive prostate cancer. New Engl. J. Med., 381, 13–24. Search in Google Scholar

Davis, I. D. (2019). Enzalutamide with standard first-line therapy in meta-static prostate cancer. New Engl. J. Med., 381, 121–131. Search in Google Scholar

Devlin, H. (2018). James P Allison and Tasuku Honjo win Nobel prize for medicine. The Guardian. https://www.theguardian.com/science/2018/oct/01/james-p-allison-and-tasuku-honjo-win-nobel-prize-for-medicine (accessed 25.04.2021). Search in Google Scholar

Eisenberger, M. (2017). Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol., 35, 3198–3206. Search in Google Scholar

Eisenhardt, A., Ohlmann, C. H., Doehn, C. (2020). Algorithmen zur Systemtherapie bei Prostata-, Urothel- und Nierenzellkarzinom. Der Urologe, 59, 533–543 (in German). Search in Google Scholar

Falkmer, U., Jarhult, J., Wersall, P., Cavallin-Stahl, E. (2003). A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol., 42 (5–6), 620–633. Search in Google Scholar

Filipovic, A., Miller, G., Bolen, J. (2020). Progress toward identifying exact proxies for predicting response to immunotherapies. Front Cell Dev. Biol., 17 (8), 155. Search in Google Scholar

Fizazi, K. (2017). Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New Engl. J. Med., 377, 352–360. Search in Google Scholar

George, D. J. (2013). Metastatic castrate resistant prostate cancer management metastatic CRPC: A cross-sectional landscape of the disease and treatments. Urology, 82, http://webedcafe.com/extern/program_media/goldjournal.net/2013/prostate_cancer/figure.php?speaker=george&figure=1 (accessed 25.04.2021). Search in Google Scholar

Grance, E., Galsky, M., Arrenz, J. A., De Santis, M., Davis, I. D., De Giorgi, U. F. F., Mencinger, M., Kikuchi, E., Garcia del Muro, X., Gumus, M., Ozguroglu, M., Rezazadeh Kalebasty, A., Park., S. H., Alekseev, B. Y., Schutz, F. A. B., Li, J. R., Mecke, A., Mariathasan, S., Thastrom, A., Bamias, A. (2019). LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Ann. Oncol., 30 (5), v888–v889. Search in Google Scholar

Heidenreich, A. (2013). Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: Results from the German compassionate-use programme. Eur. Urol., 63, 977–982. Search in Google Scholar

Hussain, M. (2018). Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New Engl. J. Med., 378, 2465–2474. Search in Google Scholar

James, N. D. (2017). Abiraterone for prostate pancer not previously treated with hormone therapy. New Engl. J. Med., 377, 338–351. Search in Google Scholar

James, N. D. (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387, 1163–1177. Search in Google Scholar

Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., Escors, D. (2011). PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med., 3 (10), 581–592. Search in Google Scholar

Klaassen, Z., Wallis, C. J. D. (2020). First line therapy for metastatic clear cell renal cell carcinoma. Kidney-cancer-today/118209-first-line-therapy-for-metastatic-clear-cell-rcc.html (accessed 24.04.2021). Search in Google Scholar

Ljungberg, B., Albiges, L., Bensalah, K., Bex, A., Giles, R.H., Hora, M., Kuczyk, M.A., Lam, T., Marconi, L., Merseburger, A. S., Powles, T., Staehler, M., Volpe, A. (2020). EAU Guidelines on Renal Cell Carcinoma. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Renal-Cell-Carcinoma-2020.pdf (accessed 24.04.2021). Search in Google Scholar

Maase, H. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol., 23, 4602–4608. Search in Google Scholar

Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A. M., Lam, T. B., Mason, M. D., van der Kwast, T. H., van der Poel, H. G., Rouviere, O., Schoots, I. G., Tilki, D., Wiegel, T. (2020) Oncology Guidelines on Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/ (accessed 24.04.2021). Search in Google Scholar

Nair, B., Wilt, T., MacDonald, R., Rutks, I. (2002). Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst. Rev., (1), CD003506. Search in Google Scholar

Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer. 12 (4), 252–264. Search in Google Scholar

Ryan, C. J. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 16, 152–160. Search in Google Scholar

Sharma, P. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol., 18, 312–322. Search in Google Scholar

Smith, M. R. (2018). Apalutamide treatment and metastasis-free survival in prostate cancer. New Engl. J. Med., 378, 1408–1418. Search in Google Scholar

Sweeney, C. J. (2015). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl. J. Med., 373, 737–746. Search in Google Scholar

Syn, N. L., Teng, M. W. L., Mok, T. S. K. Soo, R. A. (2017). De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology, 18 (12), e731–e741. Search in Google Scholar

Witjes, J. A., Bruins, H. M., Cathomas, R., Comperat, E., Cowan, N. C., Gakis, G., Hernandez, V., Lorch, A., Ribal, M. J., Thalmann, G. N., van der Heijden, A. G., Veskimae, E. (2020). EAU Guidelines on muscle-invasive and metastatic bladder cancer. https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ (accessed 24.04.2021). Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo